Institute of Materia Medica, CAMS & PUMC
Chemical Class:
Drug Target:

Publications. February 2023. Liu H, Zhu H, Fu L, Zhang W, Chen X, Wang B, Guo S, Ding Y, Wang N, Li D, Lu Y. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.  Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0139922. doi: 10.1128/aac.01399-22. Epub 2023 Jan 9. PMID: 36622240; PMCID: PMC9933650.


Publication. August 2021. Guo S, Wang B, Fu L, Chen X, Zhang W, Huang H, Lu Y. In vitro and in vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis  Antimicrob Agents Chemother Aug 16;AAC0097421. doi: 10.1128/AAC.00974-21. Online ahead of print.

Jiang J, Liu Y, Liu X, Zhang D, Huang H, Wang B, Sheng L, Li Y. Simultaneous determination of a novel oxazolidinone anti-tuberculosis OTB-658 and its metabolites in monkey blood by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Mar 15;1167:122552. doi: 10.1016/j.jchromb.2021.122552. Epub 2021 Jan 18. PMID: 33588346.

OTB-658(N-(((3S,3aS)-8-Fluoro-1-oxo-7-thiomorpholino-3a,4-dihy-dro-1H,3H-benzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl) methyl) acet-amide)

Developer Associations
Institute of Materia Medica, CAMS & PUMC